Surrozen (SRZN) Competitors

$29.87 -0.27 (-0.90%)

Closing price 04:00 PM Eastern

Extended Trading

$27.54 -2.34 (-7.82%)

As of 04:04 PM Eastern

SRZN vs. ABCL, MBX, WVE, AVBP, and KALV

Should you buy Surrozen stock or one of its competitors? MarketBeat compares Surrozen with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Surrozen include AbCellera Biologics (ABCL), MBX Biosciences (MBX), WAVE Life Sciences (WVE), ArriVent BioPharma (AVBP), and KalVista Pharmaceuticals (KALV). These companies are all part of the "pharmaceutical products" industry.

How does Surrozen compare to AbCellera Biologics?

Surrozen (NASDAQ:SRZN) and AbCellera Biologics (NASDAQ:ABCL) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations.

AbCellera Biologics has higher revenue and earnings than Surrozen. AbCellera Biologics is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Surrozen	$3.48M	98.62	-$242.03M	-$37.59	N/A
AbCellera Biologics	$79.21M	16.96	-$146.41M	-$0.48	N/A

AbCellera Biologics has a net margin of -181.75% compared to Surrozen's net margin of -4,810.50%. AbCellera Biologics' return on equity of -14.86% beat Surrozen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Surrozen	-4,810.50%	-4,055.04%	-154.08%
AbCellera Biologics	-181.75%	-14.86%	-10.62%

In the previous week, Surrozen had 14 more articles in the media than AbCellera Biologics. MarketBeat recorded 23 mentions for Surrozen and 9 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 0.72 beat Surrozen's score of 0.32 indicating that AbCellera Biologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Surrozen	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AbCellera Biologics	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

66.6% of Surrozen shares are held by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are held by institutional investors. 31.7% of Surrozen shares are held by company insiders. Comparatively, 28.4% of AbCellera Biologics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Surrozen has a beta of 0.59, suggesting that its stock price is 41% less volatile than the broader market. Comparatively, AbCellera Biologics has a beta of 1.02, suggesting that its stock price is 2% more volatile than the broader market.

Surrozen currently has a consensus price target of $42.00, suggesting a potential upside of 40.61%. AbCellera Biologics has a consensus price target of $8.17, suggesting a potential upside of 85.61%. Given AbCellera Biologics' higher possible upside, analysts plainly believe AbCellera Biologics is more favorable than Surrozen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Surrozen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Summary

AbCellera Biologics beats Surrozen on 10 of the 16 factors compared between the two stocks.

How does Surrozen compare to MBX Biosciences?

Surrozen (NASDAQ:SRZN) and MBX Biosciences (NASDAQ:MBX) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations.

66.6% of Surrozen shares are held by institutional investors. 31.7% of Surrozen shares are held by company insiders. Comparatively, 52.2% of MBX Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

MBX Biosciences has lower revenue, but higher earnings than Surrozen. MBX Biosciences is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Surrozen	$3.48M	98.62	-$242.03M	-$37.59	N/A
MBX Biosciences	N/A	N/A	-$86.97M	-$2.21	N/A

Surrozen currently has a consensus price target of $42.00, suggesting a potential upside of 40.61%. MBX Biosciences has a consensus price target of $60.22, suggesting a potential upside of 70.31%. Given MBX Biosciences' higher possible upside, analysts plainly believe MBX Biosciences is more favorable than Surrozen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Surrozen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77

MBX Biosciences has a net margin of 0.00% compared to Surrozen's net margin of -4,810.50%. MBX Biosciences' return on equity of -24.52% beat Surrozen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Surrozen	-4,810.50%	-4,055.04%	-154.08%
MBX Biosciences	N/A	-24.52%	-23.59%

In the previous week, MBX Biosciences had 7 more articles in the media than Surrozen. MarketBeat recorded 30 mentions for MBX Biosciences and 23 mentions for Surrozen. MBX Biosciences' average media sentiment score of 0.78 beat Surrozen's score of 0.32 indicating that MBX Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Surrozen	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MBX Biosciences	6 Very Positive mention(s)	7 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Surrozen has a beta of 0.59, suggesting that its stock price is 41% less volatile than the broader market. Comparatively, MBX Biosciences has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market.

Summary

MBX Biosciences beats Surrozen on 11 of the 15 factors compared between the two stocks.

How does Surrozen compare to WAVE Life Sciences?

WAVE Life Sciences (NASDAQ:WVE) and Surrozen (NASDAQ:SRZN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, earnings, dividends, analyst recommendations, valuation and profitability.

89.7% of WAVE Life Sciences shares are held by institutional investors. Comparatively, 66.6% of Surrozen shares are held by institutional investors. 24.3% of WAVE Life Sciences shares are held by insiders. Comparatively, 31.7% of Surrozen shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

WAVE Life Sciences has higher revenue and earnings than Surrozen. WAVE Life Sciences is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
WAVE Life Sciences	$71.80M	18.49	-$204.38M	-$1.06	N/A
Surrozen	$3.48M	98.62	-$242.03M	-$37.59	N/A

WAVE Life Sciences currently has a consensus price target of $27.50, suggesting a potential upside of 298.55%. Surrozen has a consensus price target of $42.00, suggesting a potential upside of 40.61%. Given WAVE Life Sciences' stronger consensus rating and higher probable upside, equities analysts plainly believe WAVE Life Sciences is more favorable than Surrozen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
WAVE Life Sciences	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.87
Surrozen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

WAVE Life Sciences has a net margin of -255.70% compared to Surrozen's net margin of -4,810.50%. WAVE Life Sciences' return on equity of -56.76% beat Surrozen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
WAVE Life Sciences	-255.70%	-56.76%	-42.80%
Surrozen	-4,810.50%	-4,055.04%	-154.08%

In the previous week, Surrozen had 20 more articles in the media than WAVE Life Sciences. MarketBeat recorded 23 mentions for Surrozen and 3 mentions for WAVE Life Sciences. WAVE Life Sciences' average media sentiment score of 0.69 beat Surrozen's score of 0.32 indicating that WAVE Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
WAVE Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Surrozen	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

WAVE Life Sciences has a beta of -1.32, suggesting that its share price is 232% less volatile than the broader market. Comparatively, Surrozen has a beta of 0.59, suggesting that its share price is 41% less volatile than the broader market.

Summary

WAVE Life Sciences beats Surrozen on 11 of the 17 factors compared between the two stocks.

How does Surrozen compare to ArriVent BioPharma?

Surrozen (NASDAQ:SRZN) and ArriVent BioPharma (NASDAQ:AVBP) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, media sentiment, profitability, dividends, valuation, analyst recommendations and institutional ownership.

Surrozen presently has a consensus price target of $42.00, suggesting a potential upside of 40.61%. ArriVent BioPharma has a consensus price target of $42.78, suggesting a potential upside of 50.52%. Given ArriVent BioPharma's stronger consensus rating and higher possible upside, analysts plainly believe ArriVent BioPharma is more favorable than Surrozen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Surrozen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.92

ArriVent BioPharma has a net margin of 0.00% compared to Surrozen's net margin of -4,810.50%. ArriVent BioPharma's return on equity of -48.98% beat Surrozen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Surrozen	-4,810.50%	-4,055.04%	-154.08%
ArriVent BioPharma	N/A	-48.98%	-45.44%

66.6% of Surrozen shares are owned by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are owned by institutional investors. 31.7% of Surrozen shares are owned by company insiders. Comparatively, 8.6% of ArriVent BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Surrozen had 14 more articles in the media than ArriVent BioPharma. MarketBeat recorded 23 mentions for Surrozen and 9 mentions for ArriVent BioPharma. Surrozen's average media sentiment score of 0.32 beat ArriVent BioPharma's score of -0.33 indicating that Surrozen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Surrozen	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ArriVent BioPharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ArriVent BioPharma has lower revenue, but higher earnings than Surrozen. ArriVent BioPharma is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Surrozen	$3.48M	98.62	-$242.03M	-$37.59	N/A
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A

Surrozen has a beta of 0.59, suggesting that its share price is 41% less volatile than the broader market. Comparatively, ArriVent BioPharma has a beta of 1.51, suggesting that its share price is 51% more volatile than the broader market.

Summary

ArriVent BioPharma beats Surrozen on 10 of the 16 factors compared between the two stocks.

How does Surrozen compare to KalVista Pharmaceuticals?

Surrozen (NASDAQ:SRZN) and KalVista Pharmaceuticals (NASDAQ:KALV) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, media sentiment, profitability, dividends, valuation, analyst recommendations and institutional ownership.

Surrozen presently has a consensus price target of $42.00, suggesting a potential upside of 40.61%. KalVista Pharmaceuticals has a consensus price target of $30.60, suggesting a potential upside of 14.35%. Given Surrozen's stronger consensus rating and higher possible upside, analysts plainly believe Surrozen is more favorable than KalVista Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Surrozen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
KalVista Pharmaceuticals	1 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.22

KalVista Pharmaceuticals has a net margin of 0.00% compared to Surrozen's net margin of -4,810.50%. KalVista Pharmaceuticals' return on equity of -214.88% beat Surrozen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Surrozen	-4,810.50%	-4,055.04%	-154.08%
KalVista Pharmaceuticals	N/A	-214.88%	-81.87%

66.6% of Surrozen shares are owned by institutional investors. 31.7% of Surrozen shares are owned by company insiders. Comparatively, 4.3% of KalVista Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Surrozen had 18 more articles in the media than KalVista Pharmaceuticals. MarketBeat recorded 23 mentions for Surrozen and 5 mentions for KalVista Pharmaceuticals. KalVista Pharmaceuticals' average media sentiment score of 0.55 beat Surrozen's score of 0.32 indicating that KalVista Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Surrozen	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
KalVista Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

KalVista Pharmaceuticals has lower revenue, but higher earnings than Surrozen. KalVista Pharmaceuticals is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Surrozen	$3.48M	98.62	-$242.03M	-$37.59	N/A
KalVista Pharmaceuticals	$1.43M	961.22	-$109.52M	-$3.95	N/A

Surrozen has a beta of 0.59, suggesting that its share price is 41% less volatile than the broader market. Comparatively, KalVista Pharmaceuticals has a beta of -0.12, suggesting that its share price is 112% less volatile than the broader market.

Summary

Surrozen beats KalVista Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Surrozen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SRZN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SRZN vs. The Competition

Export

Metric	Surrozen	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$343.21M	$3.05B	$6.29B	$12.46B
Dividend Yield	N/A	1.96%	2.79%	5.30%
P/E Ratio	-0.79	19.10	20.87	25.61
Price / Sales	98.62	278.05	521.62	63.45
Price / Cash	N/A	56.53	42.94	55.34
Price / Book	-1.23	4.36	9.86	6.71
Net Income	-$242.03M	$72.19M	$3.55B	$333.77M
7 Day Performance	-2.86%	-0.54%	-0.26%	0.40%
1 Month Performance	-6.22%	0.31%	1.39%	4.03%
1 Year Performance	359.54%	46.31%	41.07%	36.33%

Surrozen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SRZN Surrozen	3.5093 of 5 stars	$29.87 -0.9%	$42.00 +40.6%	+318.6%	$343.21M	$3.48M	N/A	80	Analyst Revision
ABCL AbCellera Biologics	3.3089 of 5 stars	$4.75 +1.9%	$8.17 +72.0%	+127.1%	$1.45B	$75.13M	N/A	500	Earnings Report
MBX MBX Biosciences	3.544 of 5 stars	$29.73 +0.4%	$53.25 +79.1%	N/A	$1.41B	N/A	N/A	N/A	Analyst Forecast Analyst Revision
WVE WAVE Life Sciences	2.7611 of 5 stars	$7.20 +0.2%	$27.50 +282.2%	+9.4%	$1.38B	$42.73M	N/A	240
AVBP ArriVent BioPharma	2.5598 of 5 stars	$29.64 -0.6%	$43.00 +45.1%	+51.5%	$1.37B	N/A	N/A	40	Earnings Report Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SRZN) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Surrozen (SRZN) Competitors

SRZN vs. ABCL, MBX, WVE, AVBP, and KALV

How does Surrozen compare to AbCellera Biologics?

Summary

How does Surrozen compare to MBX Biosciences?

Summary

How does Surrozen compare to WAVE Life Sciences?

Summary

How does Surrozen compare to ArriVent BioPharma?

Summary

How does Surrozen compare to KalVista Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRZN vs. The Competition

Surrozen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Surrozen (SRZN) Competitors

SRZN vs. ABCL, MBX, WVE, AVBP, and KALV

How does Surrozen compare to AbCellera Biologics?

Which has better valuation & earnings, SRZN or ABCL?

Is SRZN or ABCL more profitable?

Does the media prefer SRZN or ABCL?

Do insiders & institutionals have more ownership in SRZN or ABCL?

Which has more risk and volatility, SRZN or ABCL?

Do analysts prefer SRZN or ABCL?

Summary

How does Surrozen compare to MBX Biosciences?

Do insiders & institutionals have more ownership in SRZN or MBX?

Which has better valuation & earnings, SRZN or MBX?

Do analysts prefer SRZN or MBX?

Is SRZN or MBX more profitable?

Does the media prefer SRZN or MBX?

Which has more risk and volatility, SRZN or MBX?

Summary

How does Surrozen compare to WAVE Life Sciences?

Do institutionals & insiders have more ownership in WVE or SRZN?

Which has preferable earnings & valuation, WVE or SRZN?

Do analysts prefer WVE or SRZN?

Is WVE or SRZN more profitable?

Does the media favor WVE or SRZN?

Which has more volatility & risk, WVE or SRZN?

Summary

How does Surrozen compare to ArriVent BioPharma?

Do analysts recommend SRZN or AVBP?

Is SRZN or AVBP more profitable?

Do insiders and institutionals hold more shares of SRZN or AVBP?

Does the media refer more to SRZN or AVBP?

Which has higher earnings & valuation, SRZN or AVBP?

Which has more risk and volatility, SRZN or AVBP?

Summary

How does Surrozen compare to KalVista Pharmaceuticals?

Do analysts recommend SRZN or KALV?

Is SRZN or KALV more profitable?

Do insiders and institutionals hold more shares of SRZN or KALV?

Does the media refer more to SRZN or KALV?

Which has higher earnings & valuation, SRZN or KALV?

Which has more risk and volatility, SRZN or KALV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRZN vs. The Competition

Surrozen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools